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Abbreviations 
Fingolimod: FTY720 
Multiple sclerosis: MS 
Malignant Melanoma: MM 
Relapsing-remitting multiple sclerosis: RRMS 
Sphingosine-1-phosphate: S1P 
Squamous cell carcinoma of the skin: SCC 
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Introduction 
Recently, immunomodulation rather than simple immunosuppression has proven beneficial in the 
treatment of Multiple Sclerosis 1-4. Novel, effective immunomodulating agents such as fingolimod 
(FTY720) are expected to be launched in the near future. As far as published (ref), efficacy and safety 
of fingolimod are very promising (ref). To obtain long-term safety data, a close follow-up of patients 
treated with new immunomodulating agents and publication of newly detected relevant side effects 
and risks is warranted.  
 
As a functional sphingosine 1-phosphate receptor antagonist, FTY720 inhibits lymphocyte emigration 
from lymphoid organs, thereby acting as an immunomodulator 5. The results of clinical studies 
investigating FTY720 for the treatment of MS are promising 1. The development of neoplasms has 
been discussed as a potential risk. Large phase II and III studies did not show a significant risk of the 
development of certain types of cancer during the time period of observation 1, 6. However, the Phase 
II clinical study with FTY720 in MS showed a higher than expected rate of skin malignancies (basal 
cell carcinoma, squamous cell carcinoma and melanoma) 1, 7-8. As a consequence of such 
observations, annual dermatological full-skin examinations have been integrated into the clinical 
phase III trials for FTY720 in MS; however after recruitment was complete and therefore without 
baseline exam. The published data of the phase III TRANSFORMS trial for short-term application of 
FTY720 showed no melanoma in 420 patients on 1.25 mg FTY720, three melanomas in 429 patients 
on 0.5 mg FTY720, and no melanoma in 431 patients on interferon beta-1a. 9. In the phase III 
FREEDOMS trial 10 with patients treated with FTY720 over 24 months, one melanoma in 429 patients 
on 1.25 mg FTY720, no melanoma in 425 patients on 0.5 mg FTY720, and one melanoma in 418 
patients on placebo were noted. The only recently published 3- year results of a phase II study 
showed one patient with MM in the placebo/ FTY720 group after 25 months and one patient with MM 
in the FTY720 1.25 mg group after 36 months. Following this 36 months analysis no additional skin 
cancers were detected during months 36-48 8. However, no data are available yet concerning possible 
risks for continued treatment beyond the observed timeframe 8. Here, we present the case of a MS 
patient who was diagnosed with melanoma after months 4 years of FTY720 (1.25 mg) continued use 
by dermatological full-skin examination and discuss the potential underlying mechanisms and 
consequences. This represents the first melanoma case occurring under long-term treatment with 
FTY720. 
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Case report  
A 41- year- old Caucasian female was diagnosed with relapsing-remitting multiple sclerosis (RRMS, 
MS) after experiencing intermittent hypaesthesia of the right hand in February 2002 and intermittent 
ataxia of the left leg and right hand in April 2003 11. MRI of the head in 2002 showed multiple 
periventricular, juxtacortical and infratentorial, T2 hyperintensive lesions, and cerebral MRI in 2003 
showed a new T2 lesion in the right thalamus. Analysis of the cerebrospinal fluid in 2002 showed 10 
cells/μl, oligoclonal bands and an elevated IgG index of 1.8. Diagnosis of RRMS was made, and after 
providing informed consent the patient was enrolled in a double-blind, randomized, placebo-controlled, 
parallel group, multicenter study evaluating safety, tolerability and effect on MRI lesion parameters of 
FTY720 vs placebo in patients with RRMS (CFTY720D2201) in January 2004. She had been allotted 
placebo from January 2004 to September 2004 in the core trial. In September 2004 the treatment was 
switched to the active compound FTY720 1.25 mg p.o./d continuously in the extension phase of the 
study CFTY720D2201 (FTY720D2201E1). After the start of FTY720 treatment in September 2004, the 
patient had no further relapses and had no progression of neurological symptoms. MRI studies in April 
2008, April 2009 and June 2009 showed multiple inactive plaques consistent with MS, which were 
unchanged from earlier imaging studies. Apart from FTY720, the patient was on oral contraception 
with 0.15 mg Desogestrel und 0.03 mg Ethinylestradiol /d. The remainder of her medical history was 
unremarkable.  
 
On annual dermatological whole skin examination in May 2009 after 57 months of 1.25mg/d FTY720 
treatment, this patient with a skin type II, less than 50 nevi, no freckles and no signs of sun-damaged 
skin presented with an asymmetrical, irregularly pigmented macule of about 5 mm on the left 
paravertebral dorsum with central hypopigmentation and irregular borders (figure 1 - 2).This lesion had 
not been noted on dermatological examinations in the years before. On dermoscopy, the lesion 
showed an atypical network pattern with irregularly distributed brown globules and an unspecific 
pattern in the centre with a hypopigmented whitish-red zone. The atypical melanocytic lesion was 
excised completely. Histological examination showed a melanoma ex naevo with a Breslow thickness 
of 0.9 mm (figure 3a and 3b) without ulceration. S-100 serum protein as a tumour marker was within 
normal limits. Further work-up, including chest-x- ray and ultra sound examination of lymph nodes and 
abdomen, yielded no pathological findings. Treatment with FTY720 was stopped. A wide excision with 
a security margin of 1 cm was performed. Because of clinical signs of regression in spite of a Breslow 
Gelöscht: ; FREEDOMS
Gelöscht: C
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<1 mm a sentinel lymph node biopsy was performed as an exception to routinely followed Swiss 
guidelines 12. The sentinel lymph node showed a small intracapsular melanocytic naevus but no 
evidence of lymph node metastasis on histological examination. 
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Discussion 
FTY720 is a functional sphingosine 1- phosphate receptor antagonist 
Briefly, sphingosine-1-phosphate (S1P) as a lysophospholipid regulates numerous functions in intra- 
and extracellular compartments. Best known are effects on the cardiovascular and the immune 
system. Five sphingosine 1-phosphate receptors are known (S1P1 to S1P5). Phosphorylated FTY720 
binds and activates S1P1, S1P3-5, but not S1P2 13. While FTY720 is an agonist at these four S1P 
receptors, its binding leads to internalization and loss of receptor surface expression. FTY720 
intriguingly ends up being a functional S1P antagonist with inhibition of lymphocyte egress from lymph 
nodes and secondary lymphoid tissues 14. These properties have led to FTY720 being developed as a 
promising immunomodulatory drug in multiple sclerosis (MS) 1.   
 
Extended clinical trials provide new data on FTY720 in MS 
The results from ongoing clinical MS trials are encouraging. However the continued use of FTY720 
has been connected with a higher than expected rate of skin malignancies in the phase II study 8. The 
reported short-term phase II data of continued treatment up to 36 months did not show a relevant 
elevation of this incidence 7, 10. Our observed case of melanoma represents a melanoma occurring 
during extended treatment with FTY720 beyond the hitherto reported timeframe. While data on the 
role of S1P in melanoma formation is patchy, direct and indirect effects of S1P receptor modulation 
may matter for melanoma formation.  
 
Direct effects of sphingosine 1-phosphate receptor modulation on melanoma  
Sphingolipids have long been considered as rather passive structural components of cellular 
membranes. More recently, it has become evident that metabolism of sphingomyelin yields several 
lipid mediators that evoke diverse and specific responses in different cell types. The sphingomyelin 
derivate S1P has attracted particular attention in the interactions with malignant cells. S1P signalling 
has been linked with complex effects on several types of carcinoma cells via regulating migratory 
responses in epithelial tumours 15-16. Davaille et al. 17 suggested a concentration-dependent effect of 
S1P for survival and apoptosis in human hepatic myofibroblasts. 
 
For melanocytes and melanoma cells, S1P exerts an influence which seems highly dependent on the 
receptor subtypes involved. S1P protects mouse melanocytes from UVB induced apoptosis by 
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phosphorylation of both ERK and Akt and thus promotes survival 18. The migration of B16 murine 
melanoma cells could be manipulated by S1P receptor subtype expression. Mainly, S1P2, for which 
FTY720 is not a ligand, downregulated cell motility and invasion, while agonism at S1P1 and S1P3 led 
to B16 migration 19. Furthermore, S1P2 activation inhibited melanoma metastasis formation in a murine 
model, while S1P1 activation aggravated metastasis in this model 20. The balance between ceramide 
and S1P expression was found to be critical for apoptosis susceptibility in human melanoma cell lines 
in culture 21. Inhibition of angiogenesis and tumour vascularisation was shown for FTY720 with 
inhibited metastatic melanoma growth in a mouse model via decreased tumour cell proliferation and 
increased apoptosis 22. S1P can also induce apoptosis in B16 melanoma cells apparently independent 
of S1P1-3 receptors 23. Due to its peculiar properties, FTY720 acts as an agonist of S1P receptors, but 
yields functional antagonism. ItsI impact on mechanisms involved in melanoma formation and 
progression remains elusive at this point in time.  
 
Indirect effects of sphingosine 1-phosphate receptor modulation on melanoma 
Melanoma as neoplasm is in close contact with the immune system. Clinical signs include the 
spontaneous regression of primary melanoma and the development of vitiligo and halo nevi in mainly 
metastatic disease. In-depth analysis of the interplay between melanoma and the immune system over 
the last two decades has yielded a great number of mostly T-cell specific antigens. Many of these 
antigens have been applied in the context of clinical immunotherapy trials. While not successful in 
prolonging survival of patients with metastatic melanoma yet, these trials have demonstrated a clear 
induction of basic immune reactions with e.g. expansion of melanoma-specific T-cells clones against 
melanoma antigens 24.  
 
The risks of immunomodifying treatment in MS have been recognized. Natalizumab is another 
immunomodulatory agent applied against MS. Observed malignancies include lung, bladder, breast, 
colon cancer and melanoma with an overall rate of 0.6% in the natalizumab group vs. 0.2% in the 
placebo group in a short-term, placebo-controlled trial for patients with active Crohn’s disease 25. 
Association of MM and treatment with natalizumab was recently discussed controversially 26-28. In a 
larger context, immunomodulation is under consideration to increase cancer incidence in several 
disease conditions 29-32 
 
Kommentar [GH1]: Ist aus 
meiner Sicht wichtig, würde ich 
lieber nicht weglassen. Müssen GH 
und ML besprechen.  
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Conclusions 
We describe a case of melanoma development during long-term treatment with FTY720. Causality is 
speculative. However, due to possible interactions between melanoma formation and progression with 
S1P and its receptor subtypes, FTY720 may be of functional relevance for melanoma formation. 
Currently, it is not clear whether the higher than expected rate of skin malignancies in MS patients on 
FTY720 indeed exceeds the one in the general population. Ongoing clinical trials with FTY720 now 
include an annual dermatological whole-body skin examination. The incidence reported in the Phase 
III studies is based on active screening via dermatological exam and is therefore difficult to compare to 
historic cohorts. 
 
A positive family history is a known risk factor for melanoma 33-34 and  should be weighed cautiously in 
the decision to start FTY720, while a personal history or the occurrence of melanoma should lead to 
cessation of FTY720 as done in our patient. Until further long-term data emerges to better assess the 
risk of skin-cancer development during treatment with FTY720, self-examinations of the skin every 
three months and a dermatological full-skin examination annually may be the best strategy regarding 
the currently unknown long-term risk of melanoma in FTY720-treated patients. Early removal of 
melanoma is the only curative treatment for this neoplasm to date.  
 
Kommentar [ML2]: ist ein ganz 
wichtiger punkt, kann man so aber 
nicht schrieben: entweder es war 
signifikant, dann übersteigt es die 
Kontrollgruppe, oder nicht; 
(testwerte/ p zeigen). 
Gesamtbevölkerung kann dann 
wegbleiben.  
 
GH Wird von Novartis selbst so 
berichtet und formuliert. 
Signifikanzberechnungen finden 
hier keine Anwendung. Würde ich 
daher so belassen, müssen GH und 
ML besprechen.  
Gelöscht: control group or the 
one in the 
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